TNFSF13B and systemic lupus erythematosus: Specific targeting of this cytokine has proved effective in suppressing pathology, in both mouse models and human patients 3, and indeed, belimumab (an anti-BAFF monoclonal antibody) is the first SLE-specific treatment to be granted Food and Drug Administration approval in the past 50 years, although disappointingly, disease activity was reduced only in a limited number of patients during phase III trials 3,7.